<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02429050</url>
  </required_header>
  <id_info>
    <org_study_id>152002</org_study_id>
    <secondary_id>80-83600-98-3006</secondary_id>
    <nct_id>NCT02429050</nct_id>
  </id_info>
  <brief_title>Morphine for Treatment of Dyspnea in Patients With COPD</brief_title>
  <acronym>MORDYC</acronym>
  <official_title>Morphine for Palliative Treatment of Refractory Dyspnea in Patients With Advanced COPD: Benefits and Respiratory Adverse Effects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dyspnea is the most reported symptom of patients with advanced Chronic Obstructive Pulmonary
      Disease (COPD) and is undertreated. Morphine is an effective treatment for dyspnea and is
      recommended in clinical practice guidelines, but questions concerning benefits and concerns
      about respiratory adverse effects remain. For example, the effect on health-related quality
      of life and functional capacity is unknown. In one-third of the patients oral sustained
      release morphine (morphine SR) doesn't relieve dyspnea and it remains unknown whether
      severity and descriptors of breathlessness may predict a response to morphine. Finally,
      cost-effectiveness of morphine SR in this patient group is unknown. Therefore, prescription
      of morphine to patients with COPD is limited.

      Objectives of this double blind randomized controlled trial are to study the effect of oral
      administration of morphine SR on health-related quality of life, respiratory adverse effects,
      and functional capacity; to explore whether description and severity of breathlessness are
      related with a clinically relevant response to morphine and to analyse the cost-effectiveness
      of morphine SR. The study population will consist of 124 clinically stable outpatients with
      COPD and severe dyspnea despite optimal pharmacological and non-pharmacological treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will be outpatients with a confirmed diagnosis of COPD, who suffer from severe
      dyspnea despite optimal pharmacological and non-pharmacological treatment. Participants will
      be recruited at CIRO, a center for pulmonary rehabilitation in the Netherlands after they
      completed a pulmonary rehabilitation program. After providing informed consent, patients will
      be randomized. Members of the research team who perform measurements will be blinded for
      treatment allocation.

      Patients in the intervention group will receive regular clinical care and morphine SR 10mg,
      administered twice daily (20mg/24h), which can be increased after one or two weeks to three
      times per day 10mg (30mg/24h) in non-responders. Patients will be defined as non-responders
      if the mean dyspnea numeric rating scale (NRS) score was not reduced by 1 point in comparison
      with baseline. The control group will receive regular clinical care and placebo medication.
      Patients will receive morphine or placebo for four weeks. In addition, both groups will
      receive a prescription for a laxative and metoclopramide at the start of the intervention and
      will be instructed to adjust the dose as needed.

      When the intervention period has ended, participants can choose to continue morphine
      treatment. They will be followed for twelve weeks to assess their healthcare use, use of
      morphine and number of adverse effects and exacerbations.

      Measurements at baseline will include: demographics, medical history, medication,
      co-morbidities, exercise capacity, respiratory parameters, generic and disease-specific
      health-related quality of life (HRQoL), severity of dyspnea, sensory and affective dimensions
      of dyspnea, impact of dyspnea, cognition, level of daytime sleepiness, and functional
      capacity. A member of the research team will visit patients after 1 and 2 weeks in their home
      environment to assess adverse effects, compliance, exacerbations, disease-specific HRQoL,
      mobility, severity of dyspnea, and some respiratory parameters. A member of the research team
      will call the patient after 2 days and 3 weeks to assess adverse effects, compliance,
      exacerbations, and severity of dyspnea. After 4 weeks the following measurements will be
      performed: respiratory parameters, exercise capacity, general and disease-specific HRQoL,
      sensory and affective dimensions of dyspnea, impact of dyspnea, functional capacity, and
      adverse effects. Overnight oximetry will be performed in the home environment at baseline and
      after four weeks. A diary for costs and healthcare use will be filled in during four weeks.

      Measurements during the twelve weeks following the intervention include: retrospective cost
      questionnaire, generic and disease-specific quality of life severity of dyspnea and adverse
      effects.

      Statistical analyses Baseline characteristics will be compared between the intervention and
      control group using descriptive statistics. Chi square tests will be used for categorical
      variables. Independent sample T-tests and Mann-Whitney U-tests will be used for continuous
      variables, according to the variable distribution. Change in CAT-score, respiratory
      parameters and 6MWD between baseline and four weeks will be compared between patients in the
      intervention and the control group. First, mean change in CAT-score, respiratory parameters
      and 6MWD will be compared between the two groups using an independent sample T-test or
      Mann-Whitney U test, according to the variable distribution. Afterwards, multivariate
      analyses for longitudinal data will be performed. Analyses will be done using an
      intention-to-treat approach. The relationship between response to opioids and severity of
      dyspnea and descriptors of breathlessness will be explored using univariate analysis,
      followed by a binary logistic regression model. A trial-based economic evaluation will be
      performed, based on empirical data obtained in the RCT. The economic evaluation will be
      performed from the societal and healthcare perspective, the first including costs inside and
      outside the health care sector, and will follow published international guidelines. The time
      horizon of the trial-based economic evaluation will be four weeks. The outcomes of the twelve
      weeks following the intervention will be used in the model-based economic evaluation. The
      model will probably take the form of a Markov model; however this will be decided upon during
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 1, 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific health-related quality of life (COPD Assessment Test (CAT))</measure>
    <time_frame>sixteen weeks</time_frame>
    <description>Change in disease-specific health-related quality of life in four weeks measured with CAT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in partial pressure of CO2 (pCO2)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in pCO2 in four weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in partial pressure of O2 (pO2)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in pO2 in four weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Respiratory rate</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in respiratory rate in four weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pulse oximetric saturation (SpO2)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in SpO2 in four weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Transcutaneous carbon dioxide (PtcCO2)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in PtcCO2 in four weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen saturation during the night</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in oxygen saturation during the night in four weeks using overnight oximetry</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>distance walked in 6 Minute Walking Test (6-MWT)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in exercise capacity in four weeks measured with 6-MWT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Care dependency (Care Dependency Scale (CDS)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in care dependency in four weeks measured with CDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mobility (Timed 'Up &amp; Go' (TUG) test)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in mobility in four weeks measured with TUG test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sensory and affective dimensions of dyspnea (Multidimensional Dyspnea Profile (MDP)</measure>
    <time_frame>four weeks</time_frame>
    <description>Sensory and affective dimensions of dyspnea in four weeks measured with MDP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of dyspnea (Pulmonary Functional Status and Dyspnea Questionnaire, PFSDQ-M)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in impact of dyspnea in four weeks measured with PFSDQ-M</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of dyspnea (Numeric Rating Scale (NRS)</measure>
    <time_frame>sixteen weeks</time_frame>
    <description>Change in severity of dyspnea in four weeks measured with NRS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Daytime sleepiness (Epworth Sleep Questionnaire)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in level of daytime sleepiness in four weeks measured with Epworth Sleep Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognition (Montreal Cognitive Assessment, (MoCA)</measure>
    <time_frame>four weeks</time_frame>
    <description>Change in cognition in four weeks measured with MoCA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>sixteen weeks</time_frame>
    <description>Adverse effects, including nausea, vomiting, constipation, drowsiness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intake of medication</measure>
    <time_frame>four weeks</time_frame>
    <description>Number of missed medication intakes in four weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of exacerbations</measure>
    <time_frame>sixteen weeks</time_frame>
    <description>Number of exacerbations in four weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost of healthcare use in euro's</measure>
    <time_frame>sixteen weeks</time_frame>
    <description>Cost of healthcare use in euro's based on the number of hospitalizations, number and type of contact with physician, use of (professional) homecare, use of medication and absence of (voluntary) work due to illness</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>sustained release morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sustained release morphine</intervention_name>
    <description>Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD according to the current Global strategy for the diagnosis,
             management, and prevention of chronic obstructive pulmonary disease (GOLD);

          -  Optimal pharmacological treatment, including including treatment with a combination of
             a long-acting muscarinic antagonist and an ultra-long-acting Î²-agonist;

          -  Grade 3 or 4 dyspnea on the mMRC dyspnea scale;

          -  Optimal non-pharmacological treatment defined as completed a comprehensive pulmonary
             rehabilitation program.

        Exclusion Criteria:

          -  History of substance misuse;

          -  Exacerbation of COPD within two weeks of study enrolment;

          -  Waiting list for lung transplantation;

          -  Pregnant or childbearing potential not using contraception;

          -  Renal failure (creatinine clearance &lt;15mL/min);

          -  Not being able to read or fill in the questionnaires or diary;

          -  Allergy for morphine or its excipients;

          -  Concomitant use of irreversible MAO blockers;

          -  Use of opioids;

          -  History of convulsions;

          -  Head injury;

          -  Intestinal obstruction;

          -  Gastroparesis;

          -  Liver disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daisy JA Janssen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>E. FM Wouters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht UMC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy van den Berg, MSc</last_name>
    <phone>+31 (0)43 3881571</phone>
    <email>c.vandenberg@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ciro centre of expertise for chronic organ failure</name>
      <address>
        <city>Horn</city>
        <zip>6080 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy A van den Berg, MSc</last_name>
      <email>c.vandenberg@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2015</study_first_submitted>
  <study_first_submitted_qc>April 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 29, 2015</study_first_posted>
  <last_update_submitted>May 30, 2017</last_update_submitted>
  <last_update_submitted_qc>May 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Dyspnea</keyword>
  <keyword>Breathlessness</keyword>
  <keyword>Morphine</keyword>
  <keyword>Opioid</keyword>
  <keyword>Symptom Management</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

